These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 17904790
1. Aromatase inhibitor and bone. Miki Y, Suzuki T, Sasano H. Biomed Pharmacother; 2007 Oct; 61(9):540-2. PubMed ID: 17904790 [Abstract] [Full Text] [Related]
2. Aromatase inhibitors: new endocrine treatment of breast cancer. Brueggemeier RW. Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379 [Abstract] [Full Text] [Related]
4. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Hadji P, Bundred N. Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489 [Abstract] [Full Text] [Related]
5. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Jhaveri K, Halperin P, Shin SJ, Vahdat L. Breast Cancer Res Treat; 2007 Dec; 106(3):315-8. PubMed ID: 17972174 [Abstract] [Full Text] [Related]
6. Management of bone loss induced by aromatase inhibitors. Gnant M. Cancer Invest; 2006 Dec; 24(3):328-30. PubMed ID: 16809162 [Abstract] [Full Text] [Related]
7. [Bone and Men's Health. Effects of aromatase inhibitors on human osteoblasts]. Sasano H, Miki Y. Clin Calcium; 2010 Feb; 20(2):189-97. PubMed ID: 20118510 [Abstract] [Full Text] [Related]
8. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE. Oncologist; 2008 Aug; 13(8):829-37. PubMed ID: 18695261 [Abstract] [Full Text] [Related]
9. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer. Barginear M, Clotfelter A, Poznak CV. Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386 [Abstract] [Full Text] [Related]
11. The effect of aromatase inhibitors on bone metabolism. Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K. Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547 [Abstract] [Full Text] [Related]
12. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Cancer Treat Rev; 2008 Jan; 34 Suppl 1():S3-18. PubMed ID: 18515009 [Abstract] [Full Text] [Related]
14. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma. Nisslein T, Freudenstein J. Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167 [Abstract] [Full Text] [Related]
18. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Dunn BK, Ryan A. Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201 [Abstract] [Full Text] [Related]
20. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Iwase H. Breast Cancer; 2008 Feb; 15(4):278-90. PubMed ID: 18810576 [Abstract] [Full Text] [Related] Page: [Next] [New Search]